CN Patent

CN101417130B — 一种治疗ⅱ型糖尿病及其并发症的药物组合物

Assigned to LUNAN HOPE PHARMACEUTICAL Co.,Ltd. · Expires 2010-10-06 · 16y expired

What this patent protects

本发明提供了一种治疗II型糖尿病及其并发症的口服药物组合物。该药物组合物包含特定比例的一种胰岛素增敏剂和一种糖胺聚糖及辅料，制成胶囊、缓释片、泡腾片、胃漂浮片、肠溶片等。应用本发明对糖尿病及其并发症有显著的疗效。

USPTO Abstract

本发明提供了一种治疗II型糖尿病及其并发症的口服药物组合物。该药物组合物包含特定比例的一种胰岛素增敏剂和一种糖胺聚糖及辅料，制成胶囊、缓释片、泡腾片、胃漂浮片、肠溶片等。应用本发明对糖尿病及其并发症有显著的疗效。

Drugs covered by this patent

metformin-hydrochloride (METFORMIN HYDROCHLORIDE)

Patent Metadata

Patent number: CN101417130B
Jurisdiction: CN
Classification: —
Expires: 2010-10-06
Drug substance claim: No
Drug product claim: No
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd.
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.